about
Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study.Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients.Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs.Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report.Mother-to-child transmission of TT virus: sequence analysis of non-coding region of TT virus in infected mother-infant pairs.Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a.Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a.Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy.Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients.Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma.Prevalence of wild-type in NS5A-PKR protein kinase binding domain in HCV-related hepatocellular carcinoma.Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression.Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma.The appropriate method of evaluating the dynamics of hepatitis B virus in patients receiving antiviral treatment: the other side of the coin.A novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infectionOccurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antiviralsLongitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumptionMolecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruptionNatural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolatesNaive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapyGeographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated SubstitutionsA liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological studyBrief Report: Outcome of Acute Hepatitis B Virus Infection in HIV-1-Infected Patients: Possible Factors Associated With Resolution or ChronicityHIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy
P50
Q37176312-9A1F9E3D-EF4C-4C94-9631-D1522CDD3652Q38597807-8175D2C6-78C5-49BA-8831-95407E2E8352Q38888859-3057B648-9DB3-4ECA-A823-DEE6BDE792AAQ39301797-EDC1EC33-4997-440D-9A15-8AFB22B6C489Q40237283-1809B869-816E-43E7-8A32-DBA316D6F192Q40377822-FCE82EE1-1C52-42DE-B159-4011B83F07B1Q40667760-F4C5F1F0-2ADB-4CA5-B4AA-A2600A75E59FQ40856569-FD0C1D6B-8B0F-476E-9900-E054F895F328Q41634185-ECDD3DAF-5018-43F6-8AAE-D63F6CA85927Q42269060-8D260AE3-0C73-4665-91F0-A0210C821269Q42669638-8F825621-54ED-4E81-A763-75B8A1C6D5C5Q42677372-1C2D1356-FB59-47DA-907B-ABE757A3D938Q42980409-BE58884F-F19F-4C32-8859-A168E0A7E7BAQ42980441-527BE386-4DCB-4BDF-BDC2-B84A4BA3A814Q42984494-485D90F8-426F-49A3-AF59-4892BC702A53Q42987087-271DD64A-A8C8-42E4-B135-6AD0FC3F6E1BQ42988991-6507AABF-8072-4CAE-8AF7-C7C77AF10DBFQ42989246-639A00C6-3A7F-4D79-985C-8D54F3F64A8AQ42996178-7301F175-C047-4792-B37E-1C4930C4FC82Q43030555-B31ABC87-F905-462C-BE41-6D948C54E8A7Q43036292-E7DB14BE-5630-46B2-B1F6-C167A848D8C3Q43037178-AFD0A89B-C5B8-45A5-A2E4-25CB58E6F808Q43040585-96DB7420-6AF2-4D89-8990-457791BC26F1Q45423256-768EE48A-F113-4B03-8F39-895F727755FDQ56979536-3196549C-AEA3-4FF6-AABE-6F87C7513C49Q58290221-0E8802FF-5400-4AE8-97D2-3F9DDB8468E1Q58290827-A8A9FC49-B486-46D1-B924-35C96DA6DED1Q58290915-3AE19433-0C51-46AF-B08F-356A2CE01D47Q58725182-8333D2E8-427F-48C1-97D5-D2129C3DFF81Q60730879-D4571D23-4B96-4605-BBDB-CE2A62935561Q64252207-297EAB5A-F9C1-4855-88ED-7A52750BAE4BQ91761648-52D8750F-7F2F-4575-9028-FB3BE8633F04Q92708105-75F08FB4-9D23-46FB-801D-D928DE0688A4Q95277079-DAC64548-7911-47EF-92A1-1CFF99A325CB
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sabrina Bagaglio
@ast
Sabrina Bagaglio
@en
Sabrina Bagaglio
@es
Sabrina Bagaglio
@nl
type
label
Sabrina Bagaglio
@ast
Sabrina Bagaglio
@en
Sabrina Bagaglio
@es
Sabrina Bagaglio
@nl
prefLabel
Sabrina Bagaglio
@ast
Sabrina Bagaglio
@en
Sabrina Bagaglio
@es
Sabrina Bagaglio
@nl
P108
P106
P21
P31
P496
0000-0002-3671-6022